News

ascopubs.org20h
MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and mFOLFOX6 as first-line treatment in HER2+ metastatic colorectal cancer—Trial in progress.
NRG GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US). This is an ASCO Meeting Abstract from the 2023 ASCO Gastrointestinal Cancers Symposium. This abstract ...